medigraphic.com
ISSN 0188-2198 (Print)

2012, Number 2

Next >>

Rev Mex Cardiol 2012; 23 (2)

Low-dose combination therapy for hypertension: A study of therapeutic targets in routine clinical practice conditions

Gómez-Álvarez E, González-Jaimes A

Language: Spanish
References: 16
Page: 43-51
PDF size: 98.76 Kb.


ABSTRACT

Hypertension is poorly controlled in most patients. The control rate, defined as a systolic blood pressure (SBP) ‹ 140 mmHg and diastolic blood pressure (DBP) ‹ 90 mmHg, is less than 20% in Mexico. This study involving 31 research centers, carried out under real conditions was designed to establish that 6.25 mg of hydrochlorothiazide (HCTZ) given once daily in fixed combination with 2.5 mg or 5 mg of bisoprolol fumarate can contribute to achieve the control targets in patients with grade I, II or III systemic hypertension who failed to a previous antihypertensive regimen, and that these combinations are safer than the drugs alone. The results showed significant mean decreases in systolic and diastolic blood pressure of 33.3 mmHg and 18.4 mmHg respectively. The response rate was 85.7% at 32 weeks of treatment. There was a decrease in mean heart rate of 10.8 beats/min, final average heart rate was 67.05 beats per minute. The results of this study show that the combination of bisoprolol in doses of 2.5 or 5.0 mg to 6.25 mg of hydrochlorothiazide per day, has additive effects that are effective in controlling blood pressure, whether mild, moderate or severe, and that helps hypertensive patients to achieve the control goals at a very high percentage and in the short term, without affecting other systems so they are safe in hypertensive diabetic and dyslipidemic patients, and in conjunction with the heart rate regulation provides cardio-protection to patients at high cardiovascular risk. Fixed combinations of antihypertensive drugs simplify dosing regimen, improve adherence to treatment, hypertension control, decrease dose-dependent adverse effects and decrease costs as a first line treatment for hypertension.


REFERENCES

  1. Kannel WP. Risk stratification in hypertension: New insights from the Framingham Study. Am J Hypertens 2000; 13(Suppl 1): S3-S10.

  2. Olaiz-Fernández G, Rivera-Dommarco J, Shamah-Levy T, Rojas R, Villalpando-Hernández S, Hernández-Ávila M, Sepúlveda-Amor J. Encuesta Nacional de Salud y Nutrición 2006. México: Instituto Nacional de Salud Pública, 2006: 5.

  3. Rosas-Peralta M. Re-encuesta Nacional de Hipertensión Arterial (RENAHTA): Consolidación mexicana de los factores de riesgo cardiovascular. Cohorte nacional de seguimiento. Arch Cardiol Mex 2005; 75: 96-111.

  4. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-1913.

  5. Mancia G, De Backer G. 2007 Guidelines for the management of arterial hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28: 1462-1536.

  6. Chobanian AV. The seven report of the joint national Committee of prevention, detection, evaluation and treatment of high blood pressure. The JNC 7 Report. JAMA 2003; 289: 2560-2572.

  7. Prisant LM. Fixed low-dose combination in first-line treatment of hypertension. J Hypertens 2002; 20(Suppl 1): S11-S19.

  8. Frishman WH. First-line therapy option with low-dose bisoprolol fumarate and low-dose hydrochlorotiazide in patients with stage I and stage II systemic hypertension. J Clin Pharmacol 1995; 35: 182-188.

  9. Moser M. Continued importance of diuretics and beta-adrenergic blockers in the management of hypertension. Med Clin North Am 2004; 88: 167-187.

  10. Neutel JM. Low does combination therapy: An important first-line treatment in the management of hypertension. Am J Hypertens 2001; 14: 286-292.

  11. Broncel M. Bisoprolol in the treatment of hypertension in the elderly. J Hum Hypertens 1998; 12: 633-644.

  12. Cucherat M. Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in post-myocardial infarction: a meta-regression of randomized clinical trials. Eur Heart J 2007; 28: 3012-3019.

  13. Díaz A. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005; 26: 967-974.

  14. Cruickshank JM. Are we misunderstanding beta-blockers? Internat J Cardiol 2007; 120: 10-27.

  15. Milionis H, Liberopoulos EG, Goudevenos J, Bairaktari E, Seferiadis K, Elisaf M. Risk factors for first-ever acute ischemic non-embolic stroke in elderly individuals. Int J Cardiol 2005; 99: 269–275.

  16. Najarian R, Sullivan L, Kannel W, Wilson P, D’Agostino R, Wolf P. Metabolic syndrome compared to type 2 diabetes mellitus as a risk factor for stroke. Arch Intern Med 2006; 166: 2106–2111.




2020     |     www.medigraphic.com